Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
The United States Food and Drug Administration FDA has granted orphan designation for Herantis Pharma Plc’s (“Herantis”) CDNF for treatment of amyotrophic lateral sclerosis (ALS). Earlier this year the European Medicines Agency EMA issued a corresponding positive decision. 
No comment yet.
Sign up to comment
Scoop.it!
This past month the U.S. Food and Drug Administration (FDA) approved two new formulations of traditional Parkinson's therapy levodopa/carbidopa. Both therapies are designed to avoid "off" time in Parkinson's — when symptoms return before another dose of medication is due.
Scoop.it!
Health authorities warned the public anew on Saturday about health facilities and medical practitioners offering unauthorized stem cell therapy and products.
Scoop.it!
23andMe, the genetic testing startup backed by Google Ventures and Facebook billionaire Yuri Milner, will stop offering test results related to customer's health in order to comply with a warning letter sent by the Food and Drug Administration on...
Scoop.it!
The US Food and Drug Administration (FDA) will soon hold a public meeting to obtain input on ways to enhance the development of new therapies to treat amyotrophic lateral sclerosis (ALS), better known,...
Scoop.it!
In an effort to help researchers move promising therapies from the laboratory to...
|
Scoop.it!
The Food and Drug Administration has proposed a greatly simplified process for doctors to obtain experimental drugs for patients who are suffering from serious or life-threatening illnesses and have no other alternative. In a breathtaking reduction of red tape, the simplification should reduce the time it takes a doctor to apply for..............
Scoop.it!
Imagine you were terminally ill and had exhausted all conventional treatments for your sickness. Then you hear about a promising drug that had the potential to cure you, but it hadn’t been approved for use. You might be willing to give that drug a try, figuring you had nothing to lose.
Scoop.it!
Last month, the Food and Drug Administration ordered the Google-backed startup 23andMe to stop providing health information to the customers who purchase their personal genetic testing kits.
Scoop.it!
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS.
Scoop.it!
BrainStorm Cell Therapeutics , a leading developer of
adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane. BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.
|
